Superior Limbic KeratoconjunctivitisNCT00167050
The Pathogenesis of Superior Limbic Keratoconjunctivitis
An observational study of Superior Limbic Keratoconjunctivitis, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Superior Limbic Keratoconjunctivitis
- How many people
- 10 participants
- Where
- 1 siteTaiwan
- Study dates
- Jul 2005to Jun 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Superior limbic keratoconjunctivitis patients who receive conjunctiva resection
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei
Fung-Rong Hu, MD, 886-2-23123456 ext. 5189, fungrong@ha.mc.ntu.edu.tw
Yi-Chen Sun, MD, 886-968195019, yichen.sun@msa.hinet.net
About this study
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.
Read the detailed description
- Specimens collection: We will collect the specimens in two different parts. One part is to collect all the paraffinized block of the SLK patients to get fifteen copies of 5-μm section of each paraffinized block from the Department of Pathology. All the slides will be deparaffinized and rehydration for further immunohistochemistry (IHC) stain . Primary antibodies for IHC stain include chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CCR1. CCR3, CCR4, CCR5, CD30L) and matrix metalloproteinases (MMP-1, -2, -3, -9). Another part of this study is to collect the conjunctiva of SLK patients and normal control patients. This part of the clinical study is sent for IRB approval concomitantly. We will collect the conjunctiva of SLK patients when they receive conjunctival resection as the treatment in the following one year. And the normal control conjunctiva will be obtained while the patients come to our hospital for cataract surgery or retinal surgery with redundant conjunctiva noted after peritomy. The fresh conjunctiva will be stored in -80℃ before RNA isolation. All the tissue will be processed into RNA and reverse transcripted into cDNA. Polymerase chain reaction will be done with the primers, including CXCR1, CXCR2, CXCR3, CXCR4, CCR1, CCR3, CCR4, CCR5, and CD30L.
- Preparation of RNA and cDNA: Total RNA will be extracted from the conjunctiva of SLK and control groups with Trizol reagent (Life, Gaithersburg, MD, USA). One microgram of total RNA from each sample will be annealed for 5 min at 70℃ with 500 ng oligo(dT) (Fermentas, Hanover, MD, USA) and reverse transcribed to cDNA by 200u RevertAid™ M-MuLV Reverse Transcriptase (Fermentas, Hanover, MD, USA) per 20 µl reaction for 1 hr at 42℃. The reaction will be stopped by heating for 10 min at 70℃.
- Polymerase chain reaction (PCR): PCR will be performed on the resultant cDNA from each sample with specific primers for human chemokines, chemokine receptors and glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The amplification will be performed with a thermocycler. The 25-μl reaction mixture consists of 2 μl cDNA, 1 μl sense and antisense primer, 12.5 μl 2x PCR mix. Conditions for amplifying each chemokine and chemokine receptor are as follows: denaturation, 1 min at 94℃, and elongation, 3 min at 72℃. The annealing temperature and the cycle of annealing for chemokines and chemokine receptors will fit the requested temperature and the appropriate number of annealing cycles of each specific primer. At the end of amplification, the reaction mixture will be heated for 10 min at 72℃ and then cooled to 4℃. A 10-μl sample of each PCR product will be separated by performing gel electrophoresis on 2% agarose containing ethidium bromide (Sigma, St Louis, MO, USA). The 2% agarose gel will be analyzed under ultraviolet light against the DNA molecular length markers. The internal control of each sample is human GAPDH.
- Immunohistocytometry (IHC):
A pre-determined optimal dilution of the primary antibody specifically against mast cell tryptase, associated chemokines, chemokine receptors, MMPs, and inflammatory cytokines will be used for IHC. All IHC staining will be performed at room temperature. Sections are then deparaffinized in xylene and made hydrophilic by immersion in a graded series of ethanol dilutions (100, 95, 80, and 60%). All slides are immersed in antigen retrieval solution (Dako ,S3307, SA, USA) and autoclaved for 10 min. Sections are quenched with 3% fresh H2O2 for 10 min to inhibit endogenous tissue peroxidase activity that might interfere with the result of staining, and rinsed with 1x PBS for 5 min twice. Sections are further incubated in blocking serum solution for 30 min and then incubated at 37℃ for 1 h with primary antibody in a humid chamber. After washing with 1x PBS for 5 min twice, the sections are then incubated with biotinylated secondary antibody solution for 30 min. The horseradish peroxidase-conjugated streptavidin-biotin complex is subsequently spread evenly over the sections and incubated for 30 min. The sections are washed with 1x PBS for 5 min twice, then incubated with diaminobenzidine (DAB) perioxidase substrate solution for 15 min followed by wash with 1x PBS. Finally, the section are counterstained with an adequate volume of hematoxylin, and then mounted.
- Conditions
- Superior Limbic Keratoconjunctivitis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2005 (estimated)
- Study startJul 2005
- Study completionJun 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Superior Limbic KeratoconjunctivitisStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Other
- Enrolment
- 10 participants
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Fung-Rong Hu, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00167050
- Sponsor's protocol ID
- 9461700634
- Status last verified
- Jun 2005
- First submitted
- 12 Sep 2005
- Last updated
- 28 Nov 2005
- Results posted
- No
Publications
Sun YC, Hsiao CH, Chen WL, Hu FR. Overexpression of matrix metalloproteinase-1 (MMP-1) and MMP-3 in superior limbic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3701-5. doi: 10.1167/iovs.10-6324.
PubMed 21357403Sun YC, Hsiao CH, Chen WL, Wang IJ, Hou YC, Hu FR. Conjunctival resection combined with tenon layer excision and the involvement of mast cells in superior limbic keratoconjunctivitis. Am J Ophthalmol. 2008 Mar;145(3):445-452. doi: 10.1016/j.ajo.2007.10.025. Epub 2008 Jan 16.
PubMed 18201682
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Pathogenesis of Superior Limbic Keratoconjunctivitis
- ClinicalTrials.gov ID
- NCT00167050
- Acronym / sponsor ID
- 9461700634
- Conditions
- Superior Limbic Keratoconjunctivitis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10 participants
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Jul 2005
- Study completion
- Jun 2006
- First posted
- 14 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.
Detailed description
- Specimens collection: We will collect the specimens in two different parts. One part is to collect all the paraffinized block of the SLK patients to get fifteen copies of 5-μm section of each paraffinized block from the Department of Pathology. All the slides will be deparaffinized and rehydration for further immunohistochemistry (IHC) stain . Primary antibodies for IHC stain include chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CCR1. CCR3, CCR4, CCR5, CD30L) and matrix metalloproteinases (MMP-1, -2, -3, -9). Another part of this study is to collect the conjunctiva of SLK patients and normal control patients. This part of the clinical study is sent for IRB approval concomitantly. We will collect the conjunctiva of SLK patients when they receive conjunctival resection as the treatment in the following one year. And the normal control conjunctiva will be obtained while the patients come to our hospital for cataract surgery or retinal surgery with redundant conjunctiva noted after peritomy. The fresh conjunctiva will be stored in -80℃ before RNA isolation. All the tissue will be processed into RNA and reverse transcripted into cDNA. Polymerase chain reaction will be done with the primers, including CXCR1, CXCR2, CXCR3, CXCR4, CCR1, CCR3, CCR4, CCR5, and CD30L.
- Preparation of RNA and cDNA: Total RNA will be extracted from the conjunctiva of SLK and control groups with Trizol reagent (Life, Gaithersburg, MD, USA). One microgram of total RNA from each sample will be annealed for 5 min at 70℃ with 500 ng oligo(dT) (Fermentas, Hanover, MD, USA) and reverse transcribed to cDNA by 200u RevertAid™ M-MuLV Reverse Transcriptase (Fermentas, Hanover, MD, USA) per 20 µl reaction for 1 hr at 42℃. The reaction will be stopped by heating for 10 min at 70℃.
- Polymerase chain reaction (PCR): PCR will be performed on the resultant cDNA from each sample with specific primers for human chemokines, chemokine receptors and glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The amplification will be performed with a thermocycler. The 25-μl reaction mixture consists of 2 μl cDNA, 1 μl sense and antisense primer, 12.5 μl 2x PCR mix. Conditions for amplifying each chemokine and chemokine receptor are as follows: denaturation, 1 min at 94℃, and elongation, 3 min at 72℃. The annealing temperature and the cycle of annealing for chemokines and chemokine receptors will fit the requested temperature and the appropriate number of annealing cycles of each specific primer. At the end of amplification, the reaction mixture will be heated for 10 min at 72℃ and then cooled to 4℃. A 10-μl sample of each PCR product will be separated by performing gel electrophoresis on 2% agarose containing ethidium bromide (Sigma, St Louis, MO, USA). The 2% agarose gel will be analyzed under ultraviolet light against the DNA molecular length markers. The internal control of each sample is human GAPDH.
- Immunohistocytometry (IHC):
A pre-determined optimal dilution of the primary antibody specifically against mast cell tryptase, associated chemokines, chemokine receptors, MMPs, and inflammatory cytokines will be used for IHC. All IHC staining will be performed at room temperature. Sections are then deparaffinized in xylene and made hydrophilic by immersion in a graded series of ethanol dilutions (100, 95, 80, and 60%). All slides are immersed in antigen retrieval solution (Dako ,S3307, SA, USA) and autoclaved for 10 min. Sections are quenched with 3% fresh H2O2 for 10 min to inhibit endogenous tissue peroxidase activity that might interfere with the result of staining, and rinsed with 1x PBS for 5 min twice. Sections are further incubated in blocking serum solution for 30 min and then incubated at 37℃ for 1 h with primary antibody in a humid chamber. After washing with 1x PBS for 5 min twice, the sections are then incubated with biotinylated secondary antibody solution for 30 min. The horseradish peroxidase-conjugated streptavidin-biotin complex is subsequently spread evenly over the sections and incubated for 30 min. The sections are washed with 1x PBS for 5 min twice, then incubated with diaminobenzidine (DAB) perioxidase substrate solution for 15 min followed by wash with 1x PBS. Finally, the section are counterstained with an adequate volume of hematoxylin, and then mounted.
Study design
- Observational model
- Defined population
- Time perspective
- Other
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Superior limbic keratoconjunctivitis patients who receive conjunctiva resection
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2005.
- Derived from this study: PubMed 21357403Sun YC, Hsiao CH, Chen WL, Hu FR. Overexpression of matrix metalloproteinase-1 (MMP-1) and MMP-3 in superior limbic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3701-5. doi: 10.1167/iovs.10-6324.
- Derived from this study: PubMed 18201682Sun YC, Hsiao CH, Chen WL, Wang IJ, Hou YC, Hu FR. Conjunctival resection combined with tenon layer excision and the involvement of mast cells in superior limbic keratoconjunctivitis. Am J Ophthalmol. 2008 Mar;145(3):445-452. doi: 10.1016/j.ajo.2007.10.025. Epub 2008 Jan 16.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fung-Rong Hu, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Superior Limbic Keratoconjunctivitis, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Nov 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fung-Rong Hu, MD (886-2-23123456 ext. 5189, fungrong@ha.mc.ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00167050, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2005.